Should You Buy Shuttle Pharmaceuticals Holdings, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) presents a moderate quality profile with a QOC score of 3.7/10. Trading at $3.53, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.
The short answer: 0 of 0 CirclFi valuation models project upside for Shuttle Pharmaceuticals Holdings, Inc. (SHPH) at $3.53 — the models are evenly split, with a Quality Score of 3.7/10 and Value-Trap risk of 68/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Shuttle Pharmaceuticals Holdings, Inc. (SHPH) in 2026?
What Is the Bull Case vs the Bear Case for Shuttle Pharmaceuticals Holdings, Inc. (SHPH)?
| Bull case | Bear case |
|---|---|
| No active model projects meaningful upside for SHPH at $3.53. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | No active model flags significant downside for SHPH. The Value Trap score of 68/100 still argues for some caution. |
How Does SHPH Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: KAYS · NIKA · RDHL · GREH · PTPI · CTTH · AMRX · CRDL · SKYI · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like SHPH on Quality?
Closest companies to SHPH’s Quality of Company score of 3.7/10, across all industries.
- RWAX — TAP Real Estate Technologies, Inc. (QOC 3.7) · analysis
- BRBI — BRBI BR Partners S.A. (QOC 3.7) · analysis
- BENF — Beneficient (QOC 3.7) · analysis
- PBLS — Parabilis Medicines, Inc. (QOC 3.7) · analysis
- SPMC — Sound Point Meridian Capital, Inc. (QOC 3.7) · analysis
- RNA — Atrium Therapeutics, Inc. (QOC 3.7) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does SHPH Appear In?
So Is Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Worth Buying in 2026?
Shuttle Pharmaceuticals Holdings, Inc. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.
These are quantitative model outputs, not investment recommendations. Shuttle Pharmaceuticals Holdings, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About SHPH Stock?
Should I buy SHPH stock right now?
Based on CirclFi's multi-model analysis, 0 of 0 models see upside for SHPH at $3.53. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Shuttle Pharmaceuticals Holdings, Inc.?
Key risks include: an elevated Value Trap score of 68/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 3.7/10, indicating fundamental weakness; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does SHPH compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, SHPH holds a Quality Score of 3.7/10. Comparable companies include KAYS (QOC 3.9), NIKA (QOC 3.5), RDHL (QOC 4.1). The relative ranking helps investors identify whether SHPH offers better fundamental quality than alternatives in the same sector.
Is SHPH a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. SHPH's Quality Score of 3.7/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy SHPH at?
CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for SHPH.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad